Eighty-three pediatric patients underwent autologous peripheral blood stem cell transplants at a single institution and were included in a study evaluating the correlations between five engraftment parameters and the time to both neutrophil and platelet recovery. The parameters included: the number of nucleated cells per kg (TNC/kg), the absolute CD34 + cell content per kg (CD34 + /kg), the number of mononuclear cells per kg (MNC/kg), the number of BFU-E/kg, and the number of CFU-GM/kg. A two-tailed Mann-Whitney test (␣ = 0.05) was used to determine if there were significant differences between patients with neuroblastoma (n = 45) and patients with other diagnoses (n = 38). No statistically significant differences existed between neuroblastoma patients and patients with other diagnoses. Therefore, the two groups of patients were pooled together. Data were analyzed using both a univariate and multivariate correlation method and Student's ttest (␣ = 0.05). Two statistically significant logarithmic relationships were found. The first relationship was between MNC/kg and time to ANC reconstitution (P = 0.05). The second relationship was between CFU-GM/kg and time to platelet recovery (P = 0.01). Based on the statistical data, we conclude that there is no correlation between nucleated cell dose, CD34 + cell dose, and BFU-E content with either neutrophil or platelet recovery. Accordingly, in this study MNC cell dose per kilogram was the most important parameter predicting the length of time between graft infusion and neutrophil recovery while CFU-GM content per kilogram was the most important parameter predicting the length of time until platelet recovery. Bone Marrow Transplantation (2000) 25, 583-588. Keywords: PBSC; transplant; pediatrics; engraftment Autologous peripheral blood stem cell (PBSC) transplantation has been an important method of support following the use of high-dose chemotherapy with or without the administration of total body irradiation. that autologous PBSC transplants are better than autologous BM transplants for the following reasons: hematopoietic recovery after myeloablative therapy and infusion of autologous bone marrow is relatively prolonged and associated with considerable morbidity 2,3 whereas the tempo of autologous PBSC transplant recovery is faster.
that autologous PBSC transplants are better than autologous BM transplants for the following reasons: hematopoietic recovery after myeloablative therapy and infusion of autologous bone marrow is relatively prolonged and associated with considerable morbidity 2, 3 whereas the tempo of autologous PBSC transplant recovery is faster. 2, [4] [5] [6] Furthermore, autologous PBSC transplants have several other benefits over autologous BM transplants: general anesthesia can be avoided, blood-derived cells are more readily available in patients in whom iliac crests are inaccessible, there is less risk of tumor contamination 6 and multiple collections of peripheral blood may be more cost-effective than autologous bone marrow collections. Considering these factors, it is not surprising that the number of autologous PBSC transplants has been progressively increasing over the years.
Previous reports have found correlations between autologous PBSC transplant parameters and engraftment kinetics. Some of them conclude that the CFU-GM content of a graft correlates with the speed of hematopoietic recovery, 4, [7] [8] [9] [10] while others claim there is no correlation. 6, 11, 12 Furthermore, one study states there is a lack of BFU-E associated with the speed of recovery. 9 Finally, numerous papers find there is a relationship between the CD34 + cell dose and the kinetics of engraftment. 7, 12, [13] [14] [15] [16] [17] [18] [19] However, the few papers focusing on pediatric transplants include data from a relatively small group of patients. This limited patient number may lead to discrepancies in statistical results correlating infusion parameters and time to engraftment and perhaps even to the generation of contradictory results. For this reason, this report evaluates the tempo of engraftment with regard to various graft parameters in 83 pediatric autologous PBSC transplants.
Materials and methods

Patients
Between January 1992 and June 1998, 96 patients underwent autologous peripheral blood stem cell transplants. Their ages ranged from 1.3 to 23.83 years with a mean age of 8.3 years and a median age of 6.3 years. The time from diagnosis to transplant ranged from 120 days to 3598 days with a mean of 463 days and a median of 266 days. Thirteen patients were excluded from the study because of incomplete data or because they died before the engraftment. Of the remaining 83 patients, the diagnoses included: neuroblastoma (INSS stage IV) 20 (n = 45) in CR or VGPR 1 (n = 41), in PR1 (n = 1), in CR2 (n = 3), ALL (n = 5) all in CR2, rhabdomyosarcoma (n = 5) in CR1 (n = 3), Hodgkin's disease (n = 4) all in CR2, Wilm's tumor (n = 4) all in CR2, Ewings sarcoma (n = 3) in CR1 (n = 2), medulloblastoma (n = 3) all in CR2, soft tissue sarcoma (n = 2) in CR1, PNET of the pelvis (n = 2) in PR1, hepatoblastoma (n = 2) in PR2, T cell NHL (n = 2) in CR1 (n = 1), high grade glioma (n = 1) in PR3, Burkitt's lymphoma (n = 1) in CR2, germ cell tumor (brain) (n = 1) in PR2, rhabdoid tumor of the spine (n = 1) in PR1, and ANLL (n = 1) in CR1.
Cytokines for mobilization included GM-CSF in 38 patients while 47 patients received G-CSF. Pior therapy and the use of cytokines are summarized in Table 1 . All patients involved in the study had given informed consent according to institution guidelines.
All patients, with the exception of those with acute lymphoblastic leukemia received thiotepa (300 mg/m 2 ) as a 2-h infusion for 3 days (days −7, −6, −5) and cyclophosphamide 1500 mg/m 2 per day × 4 days (days −5, −4, −3, −2), for conditioning therapy. For the patients with acute leukemia the conditioning regimen included: total body irradiation (TBI) 150 cGy twice a day for 4 days (1200 cGy) with a cranial boost of 600 cGy, followed by VP-16 1000 mg/m 2 daily for 2 days as a continuous infusion and cyclophosphamide 60 mg/kg/day for 3 days. All patients had a day of rest prior to the infusion of cells. All patients received GCSF (5-10 g/kg/day) beginning at day +7 or GM-CSF (200 g/m 2 ) daily beginning at day +7 until an ANC Ͼ5000 l.
Peripheral blood stem cell harvest
The harvesting procedure was carried out in the hospital dialysis unit using either a Fenwal CS-3000 (Baxter Healthcare, Deerfield, IL, USA) or a Cobe Spectra (COBE BCT, Lakewood, CO, USA) according to the manufacturer's recommendations. In those patients who had bone marrow involvement at diagnosis, harvesting was performed after induction of remission, when the marrow was morphologically free of tumor. Some of the patients with neuroblastoma had tumor contamination of peripheral blood and bone marrow assessed by immunofluorescence prior to harvesting. 21 Anticoagulation was accomplished with acid citrate dextrose (ACD) at a ratio of 1:10-1:25 depending on the patient's hematocrit and platelet count. In those patients weighing less than 20 kg, the pheresis machine was primed with irradiated, leukocyte-depleted packed red blood cells and plasma. The target value for total collection and transplantation was a minimum of 2.0 × 10 8 mononuclear cells per kilogram of body weight.
Processing/Storage
Once a single pheresis was completed, a sample was removed for cell count, bacterial and fungal cultures, colony assay, and immunophenotypic analysis. All procedures were performed using sterile technique, under a laminar flow hood, when appropriate. Collections were soft spun to remove excess plasma and reduce the volume. Dimethyl sulfoxide (DMSO; Sigma, St Louis, MO, USA) was added as a cryoprotectant at a final concentration of 10% with a mixture of TC-199 (Gibco, Grand, Island, NY, USA) (60%) and the patient's plasma (20%). No purging was performed. Specimens were subdivided into 60 ml storage bags (Fenwal-Baxter), labeled and cooled on ice. Collections were then frozen in a controlled-rate liquid nitrogen freezer (KRYO 10, Planer, UK) at a rate of 1°C per min to −35°C, then 2°C per min to −70°C, and finally placed in liquid phase nitrogen at −196°C.
Specimen characterization Total nucleated cells per kilogram and mononuclear cells per kilogram:
Nucleated cell numbers were obtained from a flow cytometry differential generated by the Coulter JT (Coulter, Miami, FL, USA). The nuclear cell number was then divided by patient weight resulting in the total nuclear cells per kilogram body weight. The number of mononuclear cells was calculated by gating around the lymphocytes and monocytes present in the sample and adding the percentages together. This percentage was multiplied by the number of nuclear cells and then divided by the patient body weight.
Absolute CD34
+ cells per kilogram: Approximately 5 × 10 6 to 10 × 10 6 cells were stained with 10 l of fluorescent monoclonal antibodies (Becton Dickinson, San Jose, CA, USA). Samples were analyzed with the FACSort flow cytometer utilizing Lysis II program (Becton Dickinson) for analysis. Quadrants were set using CD45 FITC and CD14 PE. Isotype control was set to be between 98 and 100% negative. Granulocytes were eliminated from scattergrams by gating and backgating on the original two scattergrams, granularity vs size and granularity vs fluorescence. The percent CD34
+ cells in the sample was obtained by taking the respective percentage of the mononuclear cells indicated on the CD34 FITC/CD33 PE, CD38 FITC/CD34 PE, and HLA-DR FITC/CD34 PE scattergrams. This percentage was then multiplied by the total number of mononuclear cells and divided by the patient body weight.
Colony assay: Mononuclear cells were separated from a small sample using a Ficoll density gradient. Approximately 0.5 × 10 6 cells were added to 1 ml of methylcellulose medium (MethoCult M3630; StemCell Technologies, Vancouver, Canada) and incubated in a 37°C CO 2 incubator. The number of CFU-GM and BFU-E per 0.5 × 10 6 cells was manually counted on days 7 and 14 with several wells averaged. 22 In order to calculate the number of colony-forming cells per kilogram, the number of colonies per well was multiplied by the number of mononuclear cells infused and then divided by the patient weight.
Statistical analysis
Neuroblastoma patients (n = 45) were compared to patients with other diagnoses (n = 38) using the Mann-Whitney test. A two-tailed statistical test was performed and the alpha values were chosen to be 0.05. The infusion parameters and 585 the time to both neutrophil and platelet engraftment of the neuroblastoma patients and the patients with other diagnoses were compared using this test. Since no statistically significant differences existed between the neuroblastoma patients and the patients with other diagnoses for the infusion parameters or the times to neutrophil and platelet engraftment, the two groups of patients were pooled together and considered as one population. Data collected for each patient were analyzed according to the multiple correlation model represented by the following equation:
This model is a linear multivariate distribution measuring the strength of the relationship between the five engraftment parameters and either platelet or neutrophil reconstitution. In this study, values for the partial regression coefficient, ␤, will be found for each parameter. This coefficient measures the average change in the time to engraftment that will occur for every unit change in the engraftment parameters while other parameters are held constant. The critical values for the independent variables are 0.5 × 10 9 /l for absolute neutrophil count (ANC) and 20 × 10 6 /l for platelets. The alpha value chosen to run these calculations was 0.05 and results were considered significant if P Ͻ 0.05.
The regressions were first run including all parameters. After this regression, subsequent regressions were run if the P value was less than 0.50 in order to intensify the reliability of the results. This regression included only the parameter of interest. Following the linear regression, the natural logarithm of the numbers of cells and colonies of the infusion parameters was taken. This calculation allowed the determination of any logarithmic relationships that may exist as well as the reduction of clustering around the origin. Once again, further regressions were performed on individual parameters if the P value was less that 0.50.
The parameters included in the study are the infused number of total nucleated cells per kilogram (TNC/kg), CD34
+ cells per kilogram (CD34 + /kg), mononuclear cells per kilogram (MNC/kg), CFU-GM per kilogram (CFU-GM/kg), and the number of BFU-E (BFU-E/kg).
Results
The pre-infusion mean and ranges for each of the parameters are as follows and are expressed in either cells or colony-forming cells per kilogram: TNC/kg (4.5 × 10 . The pre-infusion data for each of the parameters are summarized in Table 2 .
Results of Mann-Whitney test between neuroblastoma patients and patients with other diagnoses
No statistically significant differences existed between the neuroblastoma patients and the patients with other diagnoses. The P values for each infusion parameter and the time to neutrophil and platelet engraftement are as follows: TNC/kg (P = 0.37), MNC/kg (P = 0.11), CD34 + /kg (P = 0.12), CFU-GM/kg (P = 0.21), BFU-E/kg (P = 0.34), time to neutrophil engraftment (P = 0.08), and time to platelet engraftment (P = 0.29). These data are summarized in Table 3 .
Results for neutrophil reconstitution
The mean time for patients to reach an ANC equal to or greater than 0.5 × 10 9 /l for 2 consecutive days was 16.4 days with a range of 8 to 65 days. The median was 14 days.
No statistically significant linear relationships existed between either TNC/kg (P = 0.07), MNC/kg (P = 0.57), CD34
+ /kg (P = 0.63), CFU-GM/kg (P = 0.58), or BFU-E/kg (P = 0.12) and the time to neutrophil engraftment.
Similarly, no statistically significant logarithmic correlation was found for TNC/kg (P = 0.96), CD34
+ /kg (P = 0.57), CFU-GM/kg (P = 0.60), and BFU-E/kg (P = 0.36). However, a significant relationship was found for MNC/kg (P = 0.05). Figure 1 depicts the log of infused MNC cells per kg vs the time to neutrophil engraftment.
Results for platelet reconstitution
The mean time for platelets to reach a density of 20.0 × 10 6 /l for 2 consecutive days was 30.7 days and the range was 8 to 210 days. The median time was 22 days.
No statistically significant linear correlations were found for any of the engraftment parameters: TNC/kg (P = 0.10), MNC/kg (P = 0.54), CD34 (P = 0.85), CFU-GM (P = 0.10), and BFU-E (P = 0.11).
Additionally, no significant logarithmic correlations were found for the following parameters: TNC/kg (P = 0.20), MNC/kg (P = 0.83), CD34 (P = 0.66), and BFU-E (P = 0.51). The small P value for the CFU-GM regression, P = 0.01, suggests that a logarithmic relationship between CFU-GM content and the time to platelet recovery exists. Figure 2 depicts the plot for the log of infused CFU-GM per kg patient body weight vs the time to platelet engraftment.
Discussion
PBSC transplants have several benefits over BM transplants including avoidance of general anesthesia, decreased risk of tumor contamination, and reduced transplantation cost as PBSC transplants have reduced infection rates and faster neutrophil reconstitution rates, 22, 23 which translates into shorter hospital lengths of stay. However, the appropriate cell doses needed to minimize the time between infusion and engraftment has remained the subject of debate.
As stated earlier in the introduction, many conflicting views concerning the critical number of CD34 + cells, 7, 12, [13] [14] [15] [16] [17] [18] [19] BFU-E, 9 and CFU-GM 4, [7] [8] [9] [10] needed to accelerate engraftment have been presented. The existence of many of these discrepancies may simply be a result of sample size variations. Diaz et al 19 found significant correlation between CD34
+ cell dose and both neutrophil and platelet recovery. However, the study presented in this paper suggests contradictory results. The differences between the two 587 . The P value for the regression is 0.05. 7 while the range was 0 to 1.7 × 10 9 . The P value is 0.01.
Bone Marrow Transplantation studies may simply be a matter of patient sample size. The group of 40 pediatric patients presented in Diaz's study is less than half of the patient sample size used in this study. Differences in patient age groups may also contribute to the correlation discrepancies. Weaver et al 15 performed an analysis of engraftment kinetics and found that a correlation existed between CD34 + cells and the kinetics of engraftment in a fairly large patient population consisting of 692 patients. However, Weaver's study focused on patients between 18 and 65 years of age whereas the patient population in this paper ranged from 1.3 to 23.83 years of age; the effects of age upon the rate of hematopoietic recovery are unknown.
Further discrepancies may stem from differences in laboratory techniques. Flow cytometry analysis and in vitro techniques vary from laboratory to laboratory making it difficult to determine the source of discrepancies for either the presence or lack of BFU-E/kg or CFU-GM/kg correlations.
The data in this study indicate that the infused number of MNC cells per kg has a logarithmic relationship with the time to ANC engraftment thereby suggesting that this parameter is the most important predictive parameter influencing the time between infusion and neutrophil engraftment. Similarly, the logarithmic relationship between the infused number of CFU-GM per kilogram and platelet recovery suggests that this parameter is the most important predictive factor influencing the time between infusion and platelet recovery. Statistically, the remaining neutrophil and platelet partial regression coefficients are essentially equal to zero. The multivariate correlation model used in this study was chosen in order to determine the strength of the relationship of each engraftment parameter upon the time to neutrophil or platelet recovery. This method was chosen as a screening method to eliminate those parameters which had little or no relationship with the speed of engraftment since correlation models may not be utilized to describe the relationship between two or more variables. However, once possibly significant relationships had been identified, simple linear regression analysis is often used to predict or estimate the value of one variable corresponding to a given value of another variable. Based on these parameters we can conclude that there is no correlation between TNC cell dose per kg, CD34
+ cell dose per kg, or BFU-E cell dose per kg with engraftment. Further prospective studies looking at other parameters that may correlate better with engraftment should be performed.
